Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients

Oncology

Volumn 66, Issue 2, 2004, Pages 132-137

  Bajetta, Emilio ^a   Beretta, Elena ^a   Di Bartolomeo, Maria ^a   Cortinovis, Diego ^a   Ferrario, Erminia ^a   Dognini, Giuseppina ^a   Toffolatti, Luisa ^a   Buzzoni, Roberto ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Fluorouracil resistance; Irinotecan; Metastatic colorectal cancer; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; METASTASIS; NAUSEA; NEUTROPENIA; PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; TOXICITY; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2342469841     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077439     Document Type: Article

References (26)

1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics. CA Cancer J Clin 2000;50:7-33.
2. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
3. Bajetta E, Di Bartolomeo M, Somma L, et al: Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil containing regimen. Eur J Cancer 1997;33:687-690.
4. Cunningham D, Pyromen S, James RD, et al: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
5. Rougier P, Van Cutsen E, Bajetta E, et al: Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
6. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 2000;335:1041-1047.
7. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;28:905-914.
8. Woynarowsky JM, Chapman WG, Napier C, et al: Oxaliplatin effects on naked and intracellular DNA (abstract). Proc Am Assoc Cancer Res 1997;38:311.
9. Levi F, Perpoint B, Garufi C, et al: Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993;29A:1280-1284.
10. Machover D, Diaz-Rubio E, De Gramont A, et al: Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-98.
11. Becourn Y, Rougier P: Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer. Semin Oncol 1998;25:23-31.
12. De Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
13. Zeghari-Squalli N, Raymond E, Cvitkovic E, et al: Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivate oxaliplatin. Clin Cancer Res 1999;5:1189-1196.
14. Erlichman C, Boerner S, Kaufmann SH: Mechanism of synergy between oxaliplatin and the topoisomerase I inhibitor SN-38. Clin Cancer Res 1999;5:3853.
15. Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P: Combination of oxaliplatin and irinotecan on human colon cancer cell lines: Activity in vitro and in vivo. Anticancer Drugs 2001; 12:741-751.
16. Wasserman E, Cuvier C, Lokiec F, et al: Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumor: Results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999;17:1751-1759.
17. Goldwasser F, Gross-Goupil M, Tigaud JM, et al: Dose escalation of CPT11 in combination with oxaliplatin using an every-two-weeks schedule: A phase I study in advanced gastrointestinal cancer patients. Ann Oncol 2000;11:1463-1470.
18. Scheithauer W, Kornek V, Raderer M, et al: Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin pretreated colorectal cancer. J Clin Oncol 1999;17:902-906.
19. Kemeny NE, Tong W, DiLauro C, Teitcher J, Gonen M, Saltz LB: Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol 2002;13:1490-1496.
20. Taron M, Plasencia C, Abad A, Martin C, Guillot M: Cytoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines. Invest New Drugs 2000;18:139-147.
21. Arnould S, Guichard S, Hennebelle I, Cassar G, Bugat R, Canal P: Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line. Biochem Pharmacol 2002;64:1215-1226.
22. Fischel Jl, Rostagno P, Formento P, Dubeuil A, Etienne MC, Milano G: Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: Results on human colon cancer cell lines. Br J Cancer 2001;84:579-585.
23. Suoglakos J, Mavroudis D, Kakolyris S, et al: Triplet combination with irinotecan plus oxaliplatin plus continuous infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial. J Clin Oncol 2002;20:2651-2657.
24. Rougier P, Lepille P, Ducreaux M, et al: Antitumor activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: A randomized, multicenter phase II study. Ann Oncol 2002;13:1558-1567.
25. Goldberg RM, Morton RF, Sargent DJ, et al: N9741: Oxaliplatin (OXAL) or CPT-11 + 5-fluorouracil/leucovorin or OXAL + CPT-11 in advanced colorectal cancer: Initial toxicity and response data from a GI Intergroup Study. 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Fla., May 18-21, 2002, abstr 511.
26. Maindrault-Goebel F, de Gramont A, Louvet C, et al: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimen (FOLFOX) in pretreated metastatic colorectal cancer. Ann Oncol 2000;11:1477-1483.